D-1082-2023 Class III Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-1082-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Jul 18, 2023 and is designated Class III. Reason for recall: Out of Specification result observed in content uniformity testing The recall status is terminated (terminated Feb 26, 2024). Affected quantity: 360 60-count bottles.

Recall details

Product Type
Drugs
Report Date
Aug 16, 2023
Initiation Date
Jul 18, 2023
Termination Date
Feb 26, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
360 60-count bottles

Product description

Dofetilide Capsules 500 mcg (0.5mg), 60-count bottle, Rx Only, Manufactured by Sun Pharmaceutical Industries Limited, Survey No. 259/15, Dadra-396 191, (U.T of D & NH), India, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512. NDC 47335-063-86

Reason for recall

Out of Specification result observed in content uniformity testing

Distribution pattern

Nationwide in the USA

Code information

Lot: DNE0217A, Exp 01/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1082-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1082-2023. Report a data issue: hello@regdatalab.com.